Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Roth Mkm reissued a “buy” rating and issued a $40.00 price objective on shares of Bio-Path in a research report on Thursday, April 18th.
View Our Latest Analysis on Bio-Path
Bio-Path Trading Down 8.0 %
Bio-Path (NASDAQ:BPTH – Get Free Report) last released its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same quarter in the previous year, the firm earned ($10.60) EPS. Sell-side analysts forecast that Bio-Path will post -18.71 EPS for the current year.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- ESG Stocks, What Investors Should Know
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.